TriSalus Life Sciences Inc.

Background

Company Name	TriSalus Life Sciences Inc.
Stock Symbol	TLSI

Submit Your Information

If you suffered a loss on your TriSalus Life Sciences Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filling out this form mean you have joined any lawsuit.

First Name*

Middle Initial

Last Name*

Email*

Phone*

If representing a Corporation, Trust, Partnership or other entity, Name of Entity

If representing an Entity, Position at Entity

Mailing Address

City

State/Province

ZIP/Postal Code

Country

Are you a current or former employee of the company?

Did you purchase any shares before January 01, 1970?

Shares Purchased

Number of Shares	Buy Date	Price Per Share	Add
Purchased quantity	Purchased month Purchased day Purchased year

Shares Sold

Number of Shares	Sell Date	Price Per Share	Add
	Sold month Sold day Sold year

Additional Comments

Background

On May 12, 2026, TriSalus reported first quarter results, including revenue of $8.90M, a decline of 2.92% year over year. The Company further announced a cut to full year revenue guidance to $54 million to $57, a cut of $5.5 million at the midpoint compared to prior guidance.

In the accompanying earnings call, management explained “the driver of this revision includes both the lower Q1 revenues from the commercial expansion and the delayed FDA clearance timing for TriNav Advance.” Management further stated FDA clearance for TriNav Advance “is now running approximately 5 months past the 30-day MDUFA review goal.”

On this, TriSalus’s stock price fell $1.89 per share, or 41.56%, to close at $2.67 on May 13, 2026, thereby injuring investors.

Submit Your Information